BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

A research team at the University of Vienna, led by medicinal chemist Markus Muttenthaler, has developed a new class of oral ...

And two weeks ago, the FDA officially proposed removing it as an active ingredient in oral over-the-counter drugs for nasal ...